Healthcare companies set for deals spree as drug patents expire
A gathering of pharmaceutical executives comes as the sector has rebounded from uncertainty over Trump’s policies
Related reading
US drugmakers threaten to withhold products from Europe over prices
Pharmaceutical companies seek to make up any lost revenue after striking deals with Donald Trump to lower costs in US
Big pharma’s scramble over the patent cliff will be costly
Groups will need to buy mature biotechs to replace revenue lost to generic competitors
US set to speed up approval for some generic drugs in blow to Big Pharma
Move is latest broadside by Trump administration against pharmaceuticals industry that fought to derail changes
Chinese drugmakers shift from copycats to global innovators
Reforms, faster development and lower costs have turbocharged growth
UK urges pharma companies to invest after reaching drug pricing deal with US
Accord will result in higher medicines spending in Britain in exchange for exemption from threatened Trump tariffs
Europe races to placate pharma as Donald Trump turns up the pressure
Tariff deals with the US have bought time but investment momentum is elsewhere